Form 6-K Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â Â FORM 6-K Â Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date as DecemberÂ 12, 2024 Commission File Number 001-35428 Â Â IMMUTEPLIMITED (Exact Name as Specified in its Charter) Â Â N/A (Translation ofRegistrantâ€™s Name) Level 32, Australia Square 264 George Street, Sydney NSW 2000, Australia (Address of principal executive office) Â Â Indicate by check mark whetherthe registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-Fâ€ ,â˜’â€fâ€fâ€fForm40-Fâ€,â˜ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1):â€,â˜ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7):â€,â˜ Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishingthe information to the Commission pursuant to RuleÂ 12g3-2(b) under the Securities Exchange Act of 1934. Yesâ€,â˜â€fâ€fâ€fNoâ€,â˜’ If â€œYesâ€ is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. Â Â Â EXHIBIT INDEX Â Exhibit Â DescriptionÂ ofÂ Exhibit 99.1 Â Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf bythe undersigned, thereunto duly authorized. Date: December 12, 2024 Â IMMUTEP LIMITED By: Â /s/ Marc Voigt Name: Â Marc Voigt Title: Â Chief Executive Officer EX-99.1 Exhibit 99.1 Â Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 Â â€¢ Â Data shows strong overall survival, progression-free survival, and durability from novel combination of eftiin combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1 Â â€¢ Â Positively, median overall survival (OS) has not yet been reached and the12-month OS rate is 67%, both well above historical controls Â â€¢ Â Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively Â â€¢ Â Treatment continues to be well tolerated SYDNEY, AUSTRALIA â€“ 12Â December 2024 â€“ Immutep Limited (ASX: IMM; NASDAQ: IMMP) (â€œImmutepâ€ orâ€œthe Companyâ€), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSDâ€™s (MerckÂ & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDAÂ® (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma(1L HNSCC) patients with negative PD-L1 expression. The new promising data presented by Martin Forster, M.D.,Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 includes strong overall survival, progression-free survival, and durability. This adds to the high response rates and favourable safety data previously reported on 12Â July 2024. Prof. Martin Forster of the UCL Cancer Institute and University College London Hospital NHS Foundation Trust, London, UK, and TACTI-003 Investigator, stated, â€œThe new survival and durability data, coupled with increasing complete responses, build on the strong response rates already established with this novel IO combination inhead and neck squamous cell cancers with PD-L1 CPS <1. This difficult-to-treat disease places a high burden on patients whounfortunately have very limited treatment options that all include chemotherapy. Collectively, these impressive results build on the potential promise of efti to improve patient outcomes and expand populations that respond to anti-PD-1.â€ Results Data as of the 31Â October 2024 cut-off date in evaluable 1L HNSCC patients (N=31) whose tumours express PD-L1 below 1 (Combined Positive Score [CPS] <1) and who typically do not respond well to anti-PD-1 therapy alone shows: Â â€¢ Â Positively, median overall survival (OS) has not yet been reached and the12-month OS rate is 67% Â â€¢ Â Promising progression-free survival (PFS) of 5.8 months Â â€¢ Â Strong durability with interim median duration of response (DOR) of 9.3 months Â â€¢ Â High 35.5% objective response rate (ORR) and 58.1% disease control rate (DCR), as reported on 12Â July Â â€¢ Â Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively1 Â â€¢ Â Efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals This data compares favourably to historical results fromanti-PD-1 therapy alone in 1L HNSCC patients with PD-L1 CPS <1 including a 7.9-monthmedian OS, 12-month OS rate of 39%, 2.1-month median PFS, 2.6-month median DOR, 5.4% ORR and 32.4% DCR with no complete responses2-3. Marc Voigt, CEO of Immutep, noted, â€œDespite the significant progress of cancer immunotherapy over the pastdecade and the positive change in the therapeutic landscape it has brought to bear, head and neck cancer patients with PD-L1 expression of less than one continue to have limited treatment options that allinclude chemotherapy. We believe this data is an encouraging step in the right direction towards potentially bringing a new approach to this underserved population, representing up to 20% of patients with this difficult disease.â€ Next Steps Patients withPD-L1 CPS <1 is an underserved patient population with limited treatment options. Immutep will continue to follow the maturing data from TACTI-003 and engage withregulatory authorities regarding potential paths forward. The ESMO IO poster is available on theÂ PostersÂ & PublicationsÂ section ofImmutepâ€™s website. KEYTRUDAÂ® is a registered trademark of Merck SharpÂ & Dohme LLC,a subsidiary of MerckÂ & Co., Inc., Rahway, NJ, USA. About Immutep Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmunedisease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolioharnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,please visit www.immutep.com. Â 1. Complete response rate was 9.6%, according to RECIST 1.1 and iRECIST, respectively, at earlier cut-off date as previously reported on 12Â July 2024 2. Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck SquamousCell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Journal of Clinical Oncology 2022 40:21, 2321-2332. Note, the 5.4%ORR and 32.4% DCR are calculated from the 37 evaluable patients with CPS <1. 3. Burtness B. et al. Abstract LB-258: Efficacy of first-line (1L)pembrolizumab by PD-L1 combined positive score <1, 1-19, and â‰¥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma(HNSCC): KEYNOTE-048 subgroup analysis. Cancer Res 15Â August 2020; 80 (16_Supplement): LBâ€“258.https://doi.org/10.1158/1538-7445.AM2020-LB-258 Australian Investors/Media: Catherine Strong,SodaliÂ & Co +61 (0)406 759 268; catherine.strong@sodali.com U.S. Media: Chris Basta, VP, Investor Relations andCorporate Communications +1 (631) 318 4000; chris.basta@immutep.com This announcement was authorised for release by the Board of Immutep Limited. Immutep Limited, LevelÂ 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia ABN: 90 009 237 889